Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q1

4587.TEDINET S100TFRV
Period2024-01-01 → 2024-03-31
Filed2024-05-15
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥4.2bn2024-01-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥28.7bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥5.0bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Operating income−¥1.1bn2024-01-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income−¥267m2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax−¥1.1bn2024-01-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥4.4bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥400m2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Net income (owners)−¥843m2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥249m2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income−¥843m2024-01-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥249m2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥69.6bnat 2024-03-31Cons.Assets IFRS
Total assets¥69.5bnat 2023-12-31Cons.Assets IFRS
Total assets¥59.8bnat 2023-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥29.7bnat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥29.1bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥40.0bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥31.8bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥40.0bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥40.3bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.8bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥27.3bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.6bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.9bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥12.4bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥7.7bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥10.4bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥1.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥381m2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥757m2024-01-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥264m2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.1bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-6.52024-01-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.412023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-1.922023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-6.52024-01-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.382023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-1.922023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio57.4%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio58.1%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio53.2%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-03-31−¥75m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-03-31−¥75m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥521m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥521m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-03-31−¥955m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥3.8bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥3.7bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥75m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-03-31−¥121m
—segment totalrevenue2024-01-01 → 2024-03-31¥4.3bn
—segment totalrevenue external2024-01-01 → 2024-03-31¥4.2bn
—segment totalrevenue intersegment2024-01-01 → 2024-03-31¥75m
—segment totalsegment profit2024-01-01 → 2024-03-31−¥1.1bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥3m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥3m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥978m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥978m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-03-31−¥381m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥4.0bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥4.0bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥3m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-03-31¥136m
—segment totalrevenue2023-01-01 → 2023-03-31¥5.0bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥5.0bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥3m
—segment totalsegment profit2023-01-01 → 2023-03-31−¥244m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 513
ItemContextValueUnit
Revenue IFRSPrior1YTDDuration4963470000JPY
Revenue IFRSCurrentYTDDuration4225166000JPY
Cost of sales IFRSPrior1YTDDuration2814443000JPY
Cost of sales IFRSCurrentYTDDuration2746491000JPY
Gross profit IFRSPrior1YTDDuration2149026000JPY
Gross profit IFRSCurrentYTDDuration1478674000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration1698672000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration1881453000JPY
Research and development expenses IFRSPrior1YTDDuration708103000JPY
Research and development expenses IFRSCurrentYTDDuration690664000JPY
Other income IFRSPrior1YTDDuration3746000JPY
Other income IFRSCurrentYTDDuration19000JPY
Other expenses IFRSPrior1YTDDuration12583000JPY
Other expenses IFRSCurrentYTDDuration5464000JPY
Operating profit loss IFRSPrior1YTDDuration-266586000JPY
Operating profit loss IFRSCurrentYTDDuration-1098888000JPY
Finance income IFRSPrior1YTDDuration5663000JPY
Finance income IFRSCurrentYTDDuration149798000JPY
Finance costs IFRSPrior1YTDDuration104728000JPY
Finance costs IFRSCurrentYTDDuration64636000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-34262000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration-90328000JPY
Profit loss before tax IFRSPrior1YTDDuration-399914000JPY
Profit loss before tax IFRSCurrentYTDDuration-1104054000JPY
Income tax expense IFRSPrior1YTDDuration-151112000JPY
Income tax expense IFRSCurrentYTDDuration-261511000JPY
Profit loss IFRSPrior1YTDDuration-248801000JPY
Profit loss IFRSCurrentYTDDuration-842543000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration-248801000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration-842543000JPY
Profit loss IFRSPrior1YTDDuration-248801000JPY
Profit loss IFRSCurrentYTDDuration-842543000JPY
Basic earnings loss per share IFRSPrior1YTDDuration-1.92
Basic earnings loss per share IFRSCurrentYTDDuration-6.50
Diluted earnings loss per share IFRSPrior1YTDDuration-1.92
Diluted earnings loss per share IFRSCurrentYTDDuration-6.50
Profit loss IFRSPrior1YTDDuration-248801000JPY
Profit loss IFRSCurrentYTDDuration-842543000JPY
Financial assets measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration14334000JPY
Financial assets measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration469448000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration14334000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration469448000JPY
Other comprehensive income IFRSPrior1YTDDuration14334000JPY
Other comprehensive income IFRSCurrentYTDDuration469448000JPY
Comprehensive income IFRSPrior1YTDDuration-234467000JPY
Comprehensive income IFRSCurrentYTDDuration-373094000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration-234467000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration-373094000JPY
Comprehensive income IFRSPrior1YTDDuration-234467000JPY
Comprehensive income IFRSCurrentYTDDuration-373094000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass